Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.1.1.7 (acetylcholinesterase)
 28,390 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Studies in vitro have suggested that acetylcholinesterase (AChE) may interact with beta-amyloid to promote deposition of amyloid plaques in the brain of patients with Alzheimer's disease. To test that hypothesis in vivo, we crossed Tg2576 mice, which express human amyloid precursor protein and develop plaques at 9 months, with transgenic mice expressing human AChE. The resulting F1 hybrids (FVB/N x [C57B6 x SJL/J]) expressed both transgenes in brain. By 6 months of age, their cerebral cortex showed authentic plaques that stained both by thioflavin S and by beta-amyloid 1-40 and 1-42 immunohistochemistry. The plaques also stained positively for other components including Cd11b, GFAP, and AChE. Plaque onset in the hybrids occurred 30-50% sooner than in the parental lines. Plaque numbers increased with age and plaques remained more numerous in the doubly transgenic animals at 9 and 12 months. Quantitative immunoassay via ELISA also showed an increase of total amyloid content in brain at 9-12 months. These histological and biochemical results support the conclusion that AChE may play a role in pathogenesis of Alzheimer's disease
 ...
PMID:Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex. 1292 60

Diazinon (DZN), an organophosphate insecticide, has been used in agriculture for several years. It is possible the residue of this compound to be recycled in the biological system. There is no report on DZN immunotoxicity potential. In the present study, we examined the immunotoxic effects of intraperitoneally administered DZN in the C57bl/6 female mice. Diazinon was administered at doses of 25, 2, and 0.2 mg/kg for 28 days (five injections per week). Animals were then sacrificed to observe the cellularity or histopathological changes in thymus, spleen, bone marrow, and peripheral blood. Furthermore, humoral and cellular functional responses such as Hemagglutination titration (HA), IgM-Plaque Forming Colony Assay (PFC), Delayed-Type-Hypersensitivity (DTH) to SRBC, and T cell subtyping (CD4/CD8) were determined. The results showed that DZN at 25 mg/kg not only could produce gross histopathological changes in thymus and spleen but also could suppress both humoral and cellular activity of the immune system. At lower doses (0.2 and 2 mg/kg) there were no observable alteration in cellularity or histology of immune tissues. However, DZN at medium dose (2 mg/kg per day) could inhibit RBC-cholinesterase and showed a mild decrease (P < 0.1) in thymus/body-weight ratio and DTH response. At dose of 0.2 mg/kg no histopathological or functional disturbances were detectable. These results indicate that DZN has immunosuppressive effects in the C57bl/6 mice at doses more than 2 mg/kg. The present results however indicate that under recommended Allowed Daily Intake (ADI) limit (<0.02 mg/kg), no observable immunotoxicity effect is expected.
 ...
PMID:Evaluation of immunotoxicity induced by diazinon in C57bl/6 mice. 1503 44